The Herbert Irving Comprehensive Cancer Center (HICCC) was designated as an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center is associated with New York-Presbyterian Hospital (NYPH). During the period 2008-2013, CUMC and NYPH committed over $350 million for i) new research initiatives in basic, clinical and population science; ii) new and expanded facilities for laboratory research and clinical activities; iii) recruitment and program restructuring; and iv) support of the Center's administrative office. A new Director, Stephen G. Emerson M.D., Ph.D. was appointed in 2012 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a 10-story building dedicated to cancer research, with state-of-the-art laboratories and clinical space in the Herbert Irving Pavilion (HIP); ii) a broad-based recruitment plan, which has already attracted 40 new faculty members to the HICCC; and iii) restructuring and expansion of the shared resources. The structure of the HICCC has been organized to increase cancer focus and interdisciplinary collaboration, and now includes 245 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Regulatory Networks and Cancer Genetics & Epigenetics), four Disease-Specific programs (Breast Cancer, Prostate Cancer, Neuro-Oncology and Lymphoid Development & Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control & Disparities). The HICCC administers and supports a total of 15 Shared Resources. During the period 2008-2013, the HICCC research activities have been documented in a total of 3057 publications of which 17% are inter-programmatic and 15% are intra-programmatic. The current NCI funding base is $26M (total direct costs), a 13% increase over the 2007 NCI funding base of $23M (total direct costs). The Center is requesting CCSG support of $2,607,495 (total direct costs) for the initial budget period.
| Sengillo, Jesse D; Lee, Winston; Bakhoum, Mathieu F et al. (2018) CHOROIDEREMIA ASSOCIATED WITH A NOVEL SYNONYMOUS MUTATION IN GENE ENCODING REP-1. Retin Cases Brief Rep 12 Suppl 1:S67-S71 |
| Kratchmarov, Radomir; Viragova, Sara; Kim, Min Jung et al. (2018) Metabolic control of cell fate bifurcations in a hematopoietic progenitor population. Immunol Cell Biol 96:863-871 |
| Xu, Christine L; Park, Karen Sophia; Tsang, Stephen H (2018) CRISPR/Cas9 genome surgery for retinal diseases. Drug Discov Today Technol 28:23-32 |
| Gartrell, Robyn D; Marks, Douglas K; Hart, Thomas D et al. (2018) Quantitative Analysis of Immune Infiltrates in Primary Melanoma. Cancer Immunol Res 6:481-493 |
| Moayedi, Yalda; Duenas-Bianchi, Lucia F; Lumpkin, Ellen A (2018) Somatosensory innervation of the oral mucosa of adult and aging mice. Sci Rep 8:9975 |
| Sengillo, Jesse D; Lee, Winston; Bilancia, Colleen G et al. (2018) Phenotypic expansion and progression of SPATA7-associated retinitis pigmentosa. Doc Ophthalmol 136:125-133 |
| Kroeger, Heike; Grimsey, Neil; Paxman, Ryan et al. (2018) The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Sci Signal 11: |
| Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503 |
| Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A : |
| Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677 |
Showing the most recent 10 out of 331 publications
